In mid-August 2019, human clinical trials were stopped in the current Ebola epidemic claiming that there are more than 2,100 people living in Africa. As a result of these results two of the drugs were discontinued in the trial. Future patients will be randomly assigned to obtain REGN-EB3 (Regeneron) or mAb114 (Riotback Biotherapeutics) in an extended phase of the study. The Institute of Biomedical Research Institute scientists in the Institute's Level 4 Biosafety contract research program carried out clinical testing of some of the compounds in the trial, working with Regeneron and the Biomedical Research and Development Authority (BARDA).
Pre-clinical data showed that all of these compounds were to some extent effective. We are committed to the commitment of these drugs and we are pleased to see that patients are recovering, as this is always the goal of our science – a positive impact on human life. "
Ricardo Carrion, Jr., Ph.D., Professor of BSL-4 Texas Biomed Contract Research Program
Ebola is a filovirus which causes haemorrhagically heavy fever and is fatal in about half of cases. Ebola virus is one of the oldest pathogens studied in the Biosafety Level 4 Laboratory at Texas Biomed. Scientists submitted a competitive bid to use non-human primates to help determine the effectiveness of all these Ebola experimental treatments. Well-documented control studies relating to animals are vital for the approval of Ebola therapies at the Food and Drug Administration (FDA). Texas Biomed is the only private biomedical research institute in the world with National Primate Research Center and Level 4 Biosafety Laboratory.
The Centers for the Prevention and Control of Disease (CDC) classified Ebola as Category A Bio-Terrorism Disease. This means that the virus can be easily transmitted from person to person, with a high mortality rate, which may cause public panic and social disruption, and requires preparation for a response.
"It is encouraging that we are moving closer to a potential cure for Ebola virus, and we are proud to have played a role in collaborating with the organizations that developed these therapies" said Dr Carrion. "It is important that we continue to study the underlying mechanisms behind the virus to develop better therapies. There is always more than one therapy against disease the best option, so it should continue. Further studies continue. "
Texas Biomedical Research Institute
.Leave a comment